Strategic Research

Cancer Genomics Group

VHIO's Cancer Genomics Group serves as a Core Facility. Our activities bridge the preclinical and clinical fields of cancer research and we provide cutting-edge applications in cancer genomics through the use of new technologies and protocol development. We perform advanced data analysis, particularly next-generation sequencing (including the Miseq platform), and  develop necessary algorithms to include new molecular profiles in our prescreening program for our interpretation of "omic" data across all research programs and projects implicated in the molecular characterization of tumors.

Strategic Goals:

  • Develop and implement improved strategies for routine patient pre-screening in a high quality setting (ISO15189 accreditation)
  • Provide cutting-edge applications in cancer genomics through the use of novel technologies and protocol development.

Main projects

  • 1.

    Wnt/Beta-Catenin pathway inhibitors as promising therapy for the treatment of lung cancer.



Bioinformatics expertise:

Group Leader:

Ana Vivancos

Bioinformatics services offered

  • SNP and indel genotyping from AmpliconSeq data

  • SNP and indel genotyping from HaloPlex data

  • SNP and indel genotyping, DNA copy number and loss of heterozygosity (LOH) analysis from ExomeSeq data

  • Differential expression analysis of mRNA from RNASeq data

  • Gene Expression and Copy Number Alteration from NanoString data